Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

Eitemau Tebyg

• Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
  gan: Iwai, Toshiki, et al.
  Cyhoeddwyd: (2016)
• Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
  gan: Masuda, Chinami, et al.
  Cyhoeddwyd: (2017)
• Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
  gan: Ishikura, Nobuyuki, et al.
  Cyhoeddwyd: (2019)
• Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
  gan: Masuda, Chinami, et al.
  Cyhoeddwyd: (2019)
• Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
  gan: Iwai, Toshiki, et al.
  Cyhoeddwyd: (2021)